About Us



Page 11234..1020..»




Jojoba Oil Market size is poised to witness a notable growth over 2020-2026 – Fractovia News

Posted: November 30, 2020 at 12:59 pm


Jojoba Oil Marketshare is poised to witness a notable growth on account of its increasing applications across personal care and pharmaceutical industries. A native to the North America region, the plant thrives in harsh climate and produces a nut that is used to make oil with several healing properties. The wax produced from the nut can be used for personal care products and medicines.

The oil can be used to treat cuts, burns, sores, and bruises and is capable of soothing both sunburns and windburns. It can also be used as a cooking oil and exhibits features that help restore scalp and hair. Jojoba oil has 50% of unsaponifiable content as compared to other vegetable oils that contain only 2-3% of the same. Application of unsaponifiable oil on skin helps improve elastin formation, giving a lustrous hair and skin look while improving elasticity.

Get sample copy of this research report @https://www.gminsights.com/request-sample/detail/2529

Company profiled in the jojoba oil marketreport based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

Manufacturers across Japan have been convincing consumers to adopt the hair care regime similar to a skincare regime. The jojoba oil market from hair care applications in Japan has witnessed a massive rise owing to the aging population in the country. Jojoba oil acts as a moisturizer to the scalp and strengthens the hair, offering healthy growth which increases its use in hair care products.

With a lower rate of birth, elderly people in Japan sum up to about 35.57 million that accounts for about 28.1% of the entire population. It has been estimated that nearly 38% of the Japanese population will be aged over 65 by the year 2065, implying a higher demand for hair care products and influencing jojoba oil market outlook in the near future.

With the rising harsh environmental conditions, consumers have been seeking products that help protect their skin. The substance is capable of removing acne issues and can act as an anti-aging agent, that has encouraged major companies to manufacture anti-agent skin products comprising jojoba oil. Asia Pacific region has been experiencing significant growth in the demand for anti-aging products, rendering a positive impact on jojoba oil market trends over the years.

Jojoba oil is known to be rich in eicosanoid acid, erucic acid, and oleic acid that exhibit their own antiseptic, anti-inflammatory as well as antioxidants properties, further raising its demand across the pharmaceutical applications. It is essentially a suitable coating or carrier used in the preparations for medicines.

The U.S jojoba oil market has been dominating the pharmaceutical trends in terms of development and consumption with prescription spending accounting for nearly USD 500 billion in 2019, Europe following closely behind. As per Pharmaceutical Research and Manufacturers, the U.S. holds over half of the worlds research and development in pharmaceuticals which also includes significant spending over the uses of jojoba oil in medicine.

Increasing awareness regarding personal healthcare with the increase in the disposable income at hand in the U.S. has proliferated the jojoba oil industry share in the region. As the products highest producer in the world, North America will happen to be the major contributor to the business outlook in the coming years.

Browse complete summary of this research report @https://www.gminsights.com/industry-analysis/jojoba-oil-market

Visit link:
Jojoba Oil Market size is poised to witness a notable growth over 2020-2026 - Fractovia News

GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference

Posted: at 12:58 pm


LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:50 pm EST.

Originally posted here:
GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference

Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd…

Posted: at 12:58 pm


NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific molecule, created by chemically conjugating a CD3- binder directly to rituximab (Rituxan®) using its multi-targeted antibody therapy enhancer (MATE) platform. Data will be presented at the upcoming 62nd American Society for Hematology (ASH) annual meeting, being held in a virtual format December 5- 8, 2020.

Read more:
Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd...

Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical Officer

Posted: at 12:58 pm


CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Arvin Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer effective immediately. Dr. Yang succeeds Dirk Huebner, M.D., who has stepped down as Chief Medical Officer but will remain with the Company until January 15, 2021, to assist with a smooth transition.

See original here:
Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. as Senior Vice President and Chief Medical Officer

Equillium to Host Virtual Investor and Analyst Day on December 4, 2020

Posted: at 12:58 pm


Review positive interim data from the study of itolizumab for the treatment of acute GVHD and pipeline programs in lupus / lupus nephritis and uncontrolled asthma

See the article here:
Equillium to Host Virtual Investor and Analyst Day on December 4, 2020

Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)

Posted: at 12:58 pm


BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia (AML). The Company previously received Breakthrough Therapy, Orphan Drug and Fast Track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes (MDS).

See the original post:
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)

Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346

Posted: at 12:58 pm


-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated ---- Non-Absorption of ALLN-346 Demonstrated ---- Advancing to Phase 1b Multiple-Ascending Dose Study and Phase 2 Proof-of-Concept Trial; Initial Data from Both Studies Expected in Second Half of 2021 --NEWTON, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced clinical data from its Phase 1 trial of ALLN-346 in healthy volunteers. ALLN-346 is an investigational, orally administered, novel urate-degrading enzyme that has been designed for activity and stability in the gastrointestinal (GI) tract, and is intended for the treatment of hyperuricemia in patients with gout and chronic kidney disease (CKD).

Read this article:
Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346

Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition

Posted: at 12:58 pm


Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS) Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS)

Read more:
Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition

Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF…

Posted: at 12:58 pm


BOSTON and COPENHAGEN, Denmark, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the publication of a paper detailing full results from a phase 2a study of GB0139 in Idiopathic Pulmonary Fibrosis (IPF) in the peer-reviewed publication European Respiratory Journal.

View original post here:
Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF...

AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe…

Posted: at 12:58 pm


DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial evaluating its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

Read this article:
AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe...

Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020

Posted: at 12:58 pm


SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at European Society of Intensive Care Medicine (ESICM) LIVES 2020, which takes place virtually Dec. 6-9, 2020.

Read this article:
Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020

Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404

Posted: at 12:58 pm


- Receptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous –

View post:
Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404

Scout Bio to Present at the Guggenheim Healthcare Talks Animal Health Veterinary Summit

Posted: at 12:58 pm


PHILADELPHIA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions, today announced that Mark Heffernan, Scout Bio’s Chief Executive Officer, will present on the “Blockbusters of 2024” panel at the upcoming Guggenheim Healthcare Talks Animal Health Veterinary Summit at 1:20 p.m. ET on Monday, December 7, 2020.

Visit link:
Scout Bio to Present at the Guggenheim Healthcare Talks Animal Health Veterinary Summit

Physician and Media Personality Dr. Drew and Aditxt CEO to Reveal and Discuss Their Personal AditxtScore™ for COVID-19 Results During…

Posted: at 12:58 pm


To Indicate Interest in a Personal AditxtScore™ for COVID-19, Visit AditxtScore.com

Read more here:
Physician and Media Personality Dr. Drew and Aditxt CEO to Reveal and Discuss Their Personal AditxtScore™ for COVID-19 Results During...

Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavirus” Therapeutic

Posted: at 12:58 pm


WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin mimetic, has the potential to treat other endemic human coronaviruses (H-CoVs), such as those causing common colds, and not just SARS-CoV-2, the novel coronavirus responsible for the ongoing global COVID-19 pandemic. Research shows Brilacidin exerted potent in vitro inhibition of multiple strains of H-CoVs. On completion of testing, the H-CoV findings are expected to be submitted for peer-review publication. The Company is evaluating these data alongside previously obtained SARS-CoV-2 data, strategizing with its scientific advisors and consultants, to develop Brilacidin as a “pan-coronavirus” therapeutic.

See the original post here:
Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavirus” Therapeutic

Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020

Posted: at 12:58 pm


CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference taking place December 1 – 3, 2020.

See the article here:
Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020

Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal…

Posted: at 12:58 pm


PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published the primary safety, efficacy, and tolerability results from the Phase 3 SECURE study evaluating Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. The results have been published online in Contraception (https://bit.ly/SECUREStudy) and will also appear in a future print edition of the journal.

The rest is here:
Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal...

Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Posted: at 12:58 pm


--First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years, if approved----Potential Approval Q3 2021 with Priority Review--

Follow this link:
Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue

Posted: at 12:58 pm


An extraordinary general meeting of Active Biotech was held on November 30, 2020.

See the original post here:
Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue

Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration

Posted: at 12:58 pm


Partnership to investigate Gain’s structurally targeted allosteric regulator candidates (STARs) in cellular models of Gaucher disease and Parkinson’s disease Partnership to investigate Gain’s structurally targeted allosteric regulator candidates (STARs) in cellular models of Gaucher disease and Parkinson’s disease

Follow this link:
Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration

Next Posts »



Page 11234..1020..»